Pfizer reports a drug-related death in tofacitinib trial

04/21/2011 | Wall Street Journal, The

Pfizer confirmed that one of four deaths during a clinical study of tofacitinib, a drug candidate for rheumatoid arthritis, was related to the drug. The company said tofacitinib-related mortality across several trials "is within the range of rates reported for biologic therapies" for the condition. Pfizer aims to market tofacitinib as an alternative to infused or injected treatments, such as Abbott Laboratories' Humira.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Actuary
Meridian Health Plan
Detroit, MI
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX